A POC and Dose-Ranging Study of HTD1801 in PSC Patients

NCT03333928 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sclerosing Cholangitis (PSC)

Interventions

DRUG: HTD1801
DRUG: Placebo

Sponsor

HighTide Biopharma Pty Ltd